Drug Discovery & DDS– category –
-
Converging Frontiers: MDPI Highlights Fusion of Synthetic and Natural Drug Research Reshaping Drug Discovery and DDS
MDPI Switzerland Overview An MDPI review highlights the convergence of synthetic chemistry and natural product research, alongside advancements in pharmaceutical engineering, biomaterials science, computational biology, and translational... -
LNP-Delivered Gene Editing Platform Targets Hepatic Lipid Metabolic Disorders for Durable, Single-Intervention Correction
Ace Therapeutics USA Overview This platform focuses on lipid nanoparticle (LNP)-delivered gene editing for heritable lipid disorders, aiming for durable, single-intervention correction of disease-driving genes in the liver. It integrates... -
RNA Therapeutics Advance with Delivery Challenges: mRNA Vaccines, siRNAs, and ASOs Drive Disease Treatment
Facebook (Ambry Genetics) USA Overview Recent publications highlight the profound impact of RNA-based therapeutic modalities, including mRNA vaccines, siRNAs, and ASOs, in treating viral infections, genetic disorders, and cancer. However... -
Micron Biomedical Secures Microneedle Contract, AbbVie’s Maviret Gains EU Approval, and Moderna’s mRNA Pipeline Advances: Diverse Drug Delivery and Discovery Progress
Drug Discovery News USA Overview The drug discovery and delivery landscape sees diverse advancements: Micron Biomedical secured a $4.5 million NIAID contract for a microneedle patch for radiation injury, highlighting advancements in pain... -
GLP-1 Agonist Tirzepatide Significantly Reduces Cardiovascular Events and Infection Risk by One-Third in Type 2 Diabetes and Obesity Patients
Technical University of Munich Germany Overview A study published in The BMJ, conducted by researchers from the Technical University of Munich and Harvard Medical School, found that tirzepatide (Mounjaro), a GLP-1 agonist, significantly ... -
HKeyBio Launches HKEY-AI2Vivo™ 1.0 Program to Accelerate In Vivo Validation for AI-Designed Candidates, Addressing Pre-IND Bottlenecks
Drug Discovery Online USA Overview HKeyBio launched HKEY-AI2Vivo™ 1.0, an AI Candidate In Vivo Validation Acceleration Program, to support AI drug discovery teams in translating AI-generated targets and molecules into in vivo pharmacolog... -
Pathos AI Licenses Alphamab’s First-in-Class TROP2/HER3 Bispecific ADC JSKN016 in $2.25 Billion Deal to Advance Breast Cancer Treatment
Fierce Biotech USA Overview Pathos AI has licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) from Alphamab, in a deal worth up to $2.25 billion ($125 million upfront, $2.1 billion in milestones). JSKN0... -
Machine Learning Accelerates Lipid Nanoparticle Design, Streamlining RNA Therapeutic Formulation Development for High Efficacy and Reduced Experimental Burden
Pharmatica USA Overview Machine learning (ML) is being applied to lipid nanoparticle (LNP) design to accelerate formulation development, improve delivery performance, and reduce experimental burden for RNA therapeutics, gene-editing syst... -
Asia-Pacific AI Drug Discovery Platforms Mature, Achieving Key Clinical Milestones
BioPharma APAC Asia-Pacific Overview AI drug discovery platforms in the Asia-Pacific region are demonstrating significant clinical traction, with Hummingbird Bioscience initiating patient dosing for its HER3-targeted ADC and Insilico Med... -
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once...
